Proteasome inhibitors attenuated cholesterol-induced cardiac hypertrophy in H9c2 cells

Hyunjung Lee, Jinyoung Park, Eunice Eun Kyeong Kim, Young Sook Yoo, Eun Joo Song

Research output: Contribution to journalArticlepeer-review

11 Scopus citations


The Ubiquitin proteasome system (UPS) plays roles in protein degradation, cell cycle control, and growth and inflammatory cell signaling. Dysfunction of UPS in cardiac diseases has been seen in many studies. Cholesterol acts as an inducer of cardiac hypertrophy. In this study, the effect of proteasome inhibitors on the cholesterol-induced hypertrophic growth in H9c2 cells is examined in order to observe whether UPS is involved in cardiac hypertrophy. The treatment of proteasome inhibitors MG132 and Bortezomib markedly reduced cellular surface area and mRNA expression of β-MHC in cholesterol-induced cardiac hypertrophy. In addition, activated AKT and ERK were significantly attenuated by MG132 and Bortezomib in cholesterol- induced cardiac hypertrophy. We demonstrated that cholesterol- induced cardiac hypertrophy was suppressed by proteasome inhibitors. Thus, regulatory mechanism of cholesterol- induced cardiac hypertrophy by proteasome inhibitors may provide a new therapeutic strategy to prevent the progression of heart failure.

Original languageEnglish
Pages (from-to)270-275
Number of pages6
JournalBMB Reports
Issue number5
StatePublished - 1 May 2016

Bibliographical note

Publisher Copyright:
© 2016 by the The Korean Society for Biochemistry and Molecular Biology.


  • Brotezomib
  • Cholesterol-induced cardiac hypertrophy
  • H9c2 cells
  • MG132
  • Proteasome inhibitors


Dive into the research topics of 'Proteasome inhibitors attenuated cholesterol-induced cardiac hypertrophy in H9c2 cells'. Together they form a unique fingerprint.

Cite this